Nintedanib
99%
- Product Code: 54239
Alias:
Related CAS number: 928326-83-4
CAS:
656247-17-5
| Molecular Weight: | 539.62 g./mol | Molecular Formula: | C₃₁H₃₃N₅O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD11974012 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | room temperature, dry |
Product Description:
Nintedanib is primarily used in the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. It works by inhibiting specific receptor tyrosine kinases that are involved in the signaling pathways leading to fibrosis, thereby slowing down the progression of the disease. Additionally, it is also used in the treatment of certain types of non-small cell lung cancer (NSCLC), particularly adenocarcinoma, in combination with chemotherapy. In this context, it helps to inhibit angiogenesis, the process by which new blood vessels form, which is crucial for tumor growth and metastasis. Nintedanib has also shown efficacy in treating systemic sclerosis-associated interstitial lung disease (SSc-ILD), where it helps to reduce lung function decline. Its ability to target multiple pathways involved in fibrosis and angiogenesis makes it a versatile therapeutic agent in managing these conditions.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | Light yellow to yellow solid |
| PURITY | 98.5 |
| PROTON NMR SPECTRUM | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.025 | 10-20 days | €65.16 |
+
-
|
| 0.100 | 10-20 days | €155.13 |
+
-
|
| 0.500 | 10-20 days | €545.58 |
+
-
|
| 1.000 | 10-20 days | €712.05 |
+
-
|
| 5.000 | 10-20 days | €2,321.62 |
+
-
|
Nintedanib
Nintedanib is primarily used in the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. It works by inhibiting specific receptor tyrosine kinases that are involved in the signaling pathways leading to fibrosis, thereby slowing down the progression of the disease. Additionally, it is also used in the treatment of certain types of non-small cell lung cancer (NSCLC), particularly adenocarcinoma, in combination with chemotherapy. In this context, it helps to inhibit angiogenesis, the process by which new blood vessels form, which is crucial for tumor growth and metastasis. Nintedanib has also shown efficacy in treating systemic sclerosis-associated interstitial lung disease (SSc-ILD), where it helps to reduce lung function decline. Its ability to target multiple pathways involved in fibrosis and angiogenesis makes it a versatile therapeutic agent in managing these conditions.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :